Peroxisome proliferator-activated receptor gamma (PPARG) inactivation has been identified as an important step in colorectal cancer (CRC) progression, although the events involved have been partially clarified. UHRF1 is emerging as a cofactor that coordinates the epigenetic silencing of tumor suppressor genes, but its role in CRC remains elusive. Here, we report that UHRF1 negatively regulates PPARG and is associated with a higher proliferative, clonogenic and migration potential. Consistently, UHRF1 ectopic expression induces PPARG repression through its recruitment on the PPARG promoter fostering DNA methylation and histone repressive modifications. In agreement, UHRF1 knockdown elicits PPARG re-activation, accompanied by positive histone marks and DNA demethylation, corroborating its role in PPARG silencing. UHRF1 overexpression, as well as PPARG-silencing, imparts higher growth rate and phenotypic features resembling those occurring in the epithelial-mesenchymal transition. In our series of 110 sporadic CRCs, high UHRF1-expressing tumors are characterized by an undifferentiated phenotype, higher proliferation rate and poor clinical outcome only in advanced stages III-IV. In addition, the inverse relationship with PPARG found in vitro is detected in vivo and UHRF1 prognostic significance appears closely related to PPARG low expression, as remarkably validated in an independent dataset. The results demonstrate that UHRF1 regulates PPARG silencing and both genes appear to be part of a complex regulatory network. These findings suggest that the relationship between UHRF1 and PPARG may have a relevant role in CRC progression.
Introduction
Epigenetics is emerging as a regulatory mechanism having a crucial role in gene expression. This term defines heritable changes in gene function that do not alter the primary DNA sequence and generally consist in methylation of cytosines within the dinucleotide CpG accompanied by a series of modifications mainly occurring at the histone tails. The different status of acetylation and methylation of specific lysine residues is considered an important mark affecting chromatin structure and gene expression (Kouzarides, 2007) . In addition to the well-known implications in several biological processes, deregulation of epigenetic mechanisms has lately been shown to contribute to cancer development (Portela and Esteller, 2010) . In contrast to a genome-wide hypomethylation that in turn increases genomic instability and activates proto-oncogenes, hypermethylation frequently occurs at tumor suppressor gene promoters, inducing transcription repression and eliciting an additional step in cancerogenesis (Issa, 2004; Jones and Baylin, 2007) . Numerous TSGs are repressed during tumorigenesis, among which peroxisome proliferator-activated receptor gamma (PPARG) has lately recalled interest (Issa, 2004; Knouff and Auwerx, 2004; Jones and Baylin, 2007) . PPARG, together with the a and b/d isoforms, belongs to the nuclear hormone receptor superfamily implicated in a wide range of physiological processes (Knouff and Auwerx, 2004; Feige et al., 2006) . Upon binding to diverse compounds and interaction with the partner retinoid X receptor, PPARG has a pivotal role in adipogenesis, inflammatory response and differentiation of many epithelial cells (Grommes et al., 2004; Knouff and Auwerx, 2004; Feige et al., 2006) . Consistently, variations in PPARG expression or gene mutations have been associated with tumorigenesis (Sarraf et al., 1999; Grommes et al., 2004; Sabatino et al., 2005; Wang and Dubois, 2008; Capaccio et al., 2010) . We recently showed that PPARG epigenetic silencing has a key role in sporadic colorectal cancer (CRC) and significantly associates with a more aggressive course and patients' worse prognosis; in the same tumors, PPARG has been shown to be an independent prognostic factor (Ogino et al., 2009; Pancione et al., 2010b) . We also showed that PPARG silencing involves DNA methylation at a specific promoter region and recruitment of MeCP2, HDAC1 and EZH2 responsible for H3K27 methylation for the maintenance of the repressed status (Pancione et al., 2010b) . MeCP2 and EZH2 levels inversely correlate with PPARG expression, as MeCP2 and EZH2 silencing re-activates PPARG, confirming their role in PPARG epigenetic repression (Pancione et al., 2010b) .
To fully accomplish the gene silencing program, other proteins orchestrate the diverse and subsequent epigenetic modifications (McCabe et al., 2009) . The Ubiquitin-like protein, UHRF1, also known as Np95 or ICBP90, coordinates DNA methylation and histone modifications to repress gene expression. Through its multiple structural domains it recruits DNA Methyl Transferases (DNMTs), methyl DNA-binding proteins such as MeCP2 and members of the Polycomb Repression Complex 2 (Unoki et al., 2004; Bostick et al., 2007; Papait et al., 2007; Sharif et al., 2007) . In non-cancer cells, UHRF1 expression fluctuates during the cell cycle (Tien et al., 2011) , whereas in cancer cells it is equally expressed in all phases (Alhosin et al., 2011) . Owing to its association with cell proliferation, UHRF1 has been suggested to serve as a putative oncogene. Despite the role of UHRF1 in DNA methylation (Bostick et al., 2007; Sharif et al., 2007; Alhosin et al., 2011) , the current knowledge on its contribution to epigenetic silencing of TSGs in primary tumors is limited to sporadic breast tumors and, recently, to lung and prostate cancer (Unoki et al., 2004; Bostick et al., 2007; Papait et al., 2007; Sharif et al., 2007; Alhosin et al., 2011; Tien et al., 2011) .
Here, we showed that UHRF1 negatively regulates PPARG and correlates with higher proliferation and migration potential in CRC cell lines. The chromatin modifications and regulatory factors recruited on the PPARG promoter were investigated along with how these changes affect the cell phenotype. In a series of sporadic CRCs, UHRF1 high expressing tumors were associated with higher tumor aggressiveness and less favorable prognosis for stages III-IV tumors. UHRF1 expression and its relationship with PPARG was appraised in our CRC series and validated in an independent, publicly available dataset. This analysis remarkably confirmed the results obtained in our tumors on the prognostic significance of low PPARG expression levels and the crucial role of the UHRF1/ PPARG association in more advanced tumor stages.
Results

UHRF1 expression in CRC cell lines and involvement in PPARG transcription regulation
We have shown that PPARG has an important role in colon tumorigenesis serving as tumor suppressor gene and is often epigenetically repressed (Pancione et al., 2010b) . As UHRF1 coordinates epigenetic silencing of TSGs (Bostick et al., 2007; Alhosin et al., 2011) , we investigated whether it modulates PPARG expression by screening a series of human CRC cell lines, HT29, HCT116 and RKO, stratified on the basis of a stable or unstable microsatellite system, and a positive or negative CpG island methylator phenotype (Issa, 2004) . Variable levels of UHRF1 were detected that inversely correlated with PPARG ( Figure 1a ). To prove that these variations reflected changes in gene transcription, UHRF1 and PPARG mRNA levels were examined by qRT-PCR. In all three-cell lines, UHRF1 and PPARG mRNAs paralleled protein levels (Figure 1b) .
To further investigate this inverse correlation and to establish whether UHRF1 is necessary and sufficient for PPARG silencing, the UHRF1 full-length cDNA was transfected in UHRF1-negative HT29 cells. After selection, several clones expressing higher UHRF1 and lower PPARG levels were isolated; among them, we decided to analyze in more detail clone #6, as it expressed five-fold higher UHRF1 and four-fold lower PPARG levels than control cells (Figure 2a ). E-cadherin and RARb, two differentiation markers (Hayashi et al., 2001) , were expressed in PPARG-positive cells and To confirm these data, we knocked-down UHRF1 in HCT116 and RKO cells. UHRF1 decreased by about 50% in both cell extracts and caused PPARG re-expression ( Figure 2b ). Note that these results refer only to the percentage of recipient cells transiently transfected with the specific short hairpin RNA (shRNA). A significant increase in E-cadherin and RARb levels was observed with respect to parental cells, suggesting that UHRF1 knockdown induces re-expression of these two differentiation markers. Transfection of HCT116 and RKO cells with an additional, independent UHRF1-shRNA (sh-UHRF1 #2) produced similar results (Supplementary Figure 1A ). Altogether these results indicate that UHRF1 is involved in PPARG deregulation.
UHRF1 binds PPARG promoter and is required for the silenced state of the gene To establish whether UHRF1 is directly involved in PPARG downregulation, we carried out chromatin immunoprecipitation (ChIP) assays on the PPARG promoter region extending from -368 to -166 with respect to the transcription start site in HT29, HCT116 and RKO cells (Figures 3a and b ). This segment is highly enriched in CpG motifs and is selectively methylated in PPARG-negative cells, thus having a crucial role in silencing this gene. Figure 3c illustrates these characteristics along with the results of the bisulphite sequencing of the same region; part of these results have previously been reported (Pancione et al., 2010b) . UHRF1 was engaged at very low levels in HT29 cells, more in HCT116 and even more in RKO cells, confirming the inverse relationship with PPARG expression (Figure 3a ). In line with the notion that UHRF1 interacts and recruits DNMTs to silence transcription of target genes (Meilinger and Fellinger, 2009; Alhosin et al., 2011) , we analyzed DNMT1, DNMT3a and 3b. DNMT1 and DNMT3a were detected at low, if any, levels on the PPARG promoter in all three cell lines (Figure 3a) , whereas DNMT3b was engaged only slightly in HT29, more in HCT116 and even more in RKO cells. In western blot analysis, DNMT3a was almost undetectable in all three-cell lines, whereas DNMT1 showed higher but similar levels. DNMT3b, instead, was expressed at higher levels in HCT116 and RKO cells, paralleling its recruitment on PPARG promoter (Supplementary Figure 2A) . Co-immunoprecipitation assays confirmed the direct, physical interaction between UHRF1 and DNMT3b in our cellular model. The specificity of the binding was demonstrated by the absence of immunoprecipitated complexes using an anti b-actin antibody (Supplementary Figure 2B ). As far as histone modifications, H4K16ac, a positive histone mark, was recruited only in PPARG-positive HT29 cells. In contrast, H3K9me3 and H3K27me3, two repressive histone marks, were poorly associated with the PPARG promoter in HT29 cells while were enriched in PPARG-negative cells. H3K9me2, another repressive mark, was only slightly associated with the promoter. In agreement with these results, among the H3K9 methyltransferases, Suv39H1, but not G9a, was present on the promoter only in PPARG-negative cells. To validate the recruitment of these factors on the PPARG promoter, UHRF1 and PPARG in colon tumorigenesis L Sabatino et al two additional promoter regions from E-cadherin and GAPDH were employed as positive and negative controls, respectively. E-cadherin promoter is reported to recruit DNMT1 and DNMT3a in prostate cancer cell lines (Babbio et al., 2012) . The GAPDH promoter, in contrast, is not affected by epigenetic repression. The results obtained confirmed the data reported (Supplementary Figure 2C) . ChIP analysis carried out in clone #6 revealed that UHRF1 was more engaged on the PPARG promoter than HT29 parental cells; a similar pattern was observed for DNMT3b, H3K9me3, H3K9me2 and H3K27me3, whereas the inverse result was obtained for H4K16ac ( Figure 3b ). In UHRF1-silenced cells, in contrast, UHRF1 was depleted from 
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L Sabatino et al the PPARG promoter and this was accompanied by a reduction of DNMT3b, H3K9me3, H3K9me2 and H3K27me3 and an increase of H4K16ac, in line with PPARG transcription re-activation. These data suggest that in the CRC cell lines PPARG silencing is strictly dependent on UHRF1 levels and its recruitment on the promoter. In turn, DNMT3b, among the DNA methylating enzymes, appears to be more engaged, probably reflecting the different levels in the cell lines analyzed.
To verify whether the chromatin changes on the PPARG promoter associate with DNA methylation, we performed MS-PCR analysis on the 'M3' (À358 to À235) and the 'M2' (À270 to À151) regions in HT 29 clone #6, in HCT116 and RKO UHRF1-depleted cells. The 'M3' segment is unmethylated in PPARG-positive and methylated in PPARG-negative cells, whereas the 'M2' region is methylated in both cell types (Pancione et al., 2010b) . In HT29 clone #6, the unmethylated M3 region became methylated; in UHRF1-silenced HCT116, the partially methylated M3 region became fully unmethylated, whereas in UHRF1-silenced RKO cells, the unmethylated band, absent in controls, became detectable ( Figure 3d ). We also assessed the amount of 5-MeC present on the À368 to À166 region in all cell lines by a quantitative methylated DNA immunoprecipitation assay. The results demonstrated a significative increase of DNA methylation in clone #6 and a significative reduction in UHRF1-silenced cells. Collectively, we provide evidence that UHRF1 is a key regulator of the repressive epigenetic pattern established on the PPARG promoter in CRC cells.
Proliferative and phenotypic analysis of cells with an overexpressed or silenced UHRF1 As PPARG acts as a tumor suppressor gene, we hypothesized that variations in UHRF1 levels and hence in PPARG content, might alter the CRC cells phenotype. We first verified whether UHRF1 could affect cell viability of clone #6 by MTT assays in comparison with parental HT29 cells (Figure 4a ). Clone #6 viability at 72 h was 47% higher than controls. This feature was directly correlated with lower levels of p21 and p27, two known CDK inhibitors, than parental cells in western blot analysis. In contrast, two proliferation markers, cyclin A and cyclin D1 clearly increased in clone #6 with respect to HT29 cells (Figure 4b) . In a colony focus-forming assay, the number and the size of the foci generated by clone #6 were four-fold higher than those produced by the HT29 parental cells (Figure 4c ). Cell migration, tested by the wound-healing assay, showed that the open wound area at 24 h was more reduced in clone #6 than in HT29 control cells (60% vs 90%), indicating a higher migration potential (Figure 4d ). In addition, clone #6 cell morphology revealed some striking differences. HT29 cells tend to form aggregates with a typical polyhedral form; clone #6 cells, instead, grow scattered with a tendency to become elongated, to form protusions and acquire a fibroblastlike shape (Figure 4e ). These features resemble those observed in cells undergoing epithelial-mesenchymal transition (EMT) (Burchill et al., 1995; Kumar et al., 2010) . To verify this, we checked the expression of some mesenchymal and epithelial markers by qRT-PCR. A three and nine-fold increase of vimentin and N-cadherin mRNAs, respectively, was observed in clone #6, accompanied by a remarkable reduction of cytokeratin 20 (CK20) and E-cadherin mRNAs (Figure 4e ). To further assess whether these growth and phenotypic modifications can be attributed to UHRF1, we performed the same analyses in UHRF1-depleted HCT116 and RKO cells, obtained as previously described: a 40% lower cell viability than their parental cells was observed in MTT assays at 72 h (Figure 5a ). In the same depleted cells, p21 and p27 protein levels were higher and cyclin A and D1 reduced in comparison with parental HCT116 and RKO cells (Figure 5b) . A caspase-3 activation assay, performed to assess the apoptosis level, revealed in UHRF1 silenced cells a 100 and 30% higher activity than the corresponding HCT116 and RKO parental cells, respectively, (Figure 5c ). These results were confirmed in TUNEL assays (Supplementary Figure 3A) and FACS analysis (data not shown). Finally, UHRF1-silenced cells also had about 30-40% lower migration ability than parental cells in a wound-healing assay (Figure 5d) . A pronounced mesenchymal phenotype was proved by the high N-cadherin and vimentin and by the low E-cadherin and CK20 mRNAs levels in HCT116 and RKO cells. UHRF1 silencing, in contrast, induced their substantial increase (Supplementary Figure 3B) . Remarkably, the changes in the expression of EMT markers are very similar to those observed in PPARG-negative (HCT116 and RKO) and PPARGsilenced (HT29) cells (Supplementary Figure 3C) . Also the growth and morphological characteristics of these latter cells (Pancione et al., 2010b) are similar to those displayed by the UHRF1 silenced cells presented here. All together these data indicate that UHRF1 influences cell growth, migration and apoptosis mainly through PPARG-silencing. Further studies are required to elucidate whether UHRF1 overexpression elicits cell modifications independent from PPARG.
UHRF1 expression in normal colonic mucosa and CRC tissues To establish whether our findings have a potential biomedical relevance in vivo, we evaluated UHRF1 expression in colon tissues by immunohistochemistry. In the normal colonic mucosa, a positive UHRF1 nuclear immunostaining was confined to the proliferative compartment corresponding to the lower third of the colonic crypts, overlapping Ki67 staining, a wellknown proliferative marker (Lorenzato et al., 2005) (Figure 6a ). UHRF1 expression was assessed also in 110 primary tumors by the same technique. A moderate or weak nuclear positivity was detected in 44 cases (40%), classified as low UHRF1-expressing tumors (Figure 6b ). An intense and diffuse staining was, instead, observed in 66 cases (60%), classified as high UHRF1-expressing tumors. Ki67 staining strongly correlated with UHRF1 positivity, as determined by calculating the H score (R ¼ 0.805; Po0.001) (Supplementary Figure 4A ) (Bruna et al., 2007) . The inverse correlation between UHRF1 and PPARG mRNA expression found in vitro was tested by qRT-PCR in vivo and, remarkably, the same association was found (Figure 6c ). Finally, UHRF1 and PPARG protein levels, assessed by western blot, mirrored the mRNA levels in all samples investigated, some representative samples of which are shown in Supplementary Figure 4B .
Association of UHRF1 expression with patients' clinico-pathological parameters We then correlated UHRF1 expression in tumor tissues with the clinico-pathological characteristics of the patients. Interestingly, low and high UHRF1 nuclear staining was significantly related to the tumor grade (low grade ¼ G1/G2 vs high grade ¼ G3/G4) (Figure 6d ). No significant correlation was found with patients' age, gender, tumor size and TNM (P40.05). UHRF1 was also associated with patients' survival rate. The median survival time for all patients was 64 months and cancer related death occurred in 30 cases (28%). When all cases (n ¼ 110) were considered (stages I-IV), no significant trend was observed between high and low UHRF1-expressing tumors and the overall survival by the Kaplan-Meier curve (data not shown). However, the same analysis conducted on stages III-IV patients-only (n ¼ 45) demonstrated that the likelihood of death from disease was significantly higher in the group overexpressing UHRF1 (Figure 6e) Figures 4C and 4D ). These data confirm the pivotal role of PPARG silencing in colon tumorigenesis (Pancione et al., 2010b) and suggest a role for UHRF1 in tumor progression. 
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The correlation of UHRF1 and PPARG expression with patients' prognosis is validated in an independent CRC dataset The role of UHRF1 in tumor development and its association with patients' prognosis was evaluated in an independent publicly available dataset constituted by a series of 232 patients. We divided the cohort in two groups according to high or low UHRF1 expression and estimated the survival function by the Kaplan-Meier method. UHRF1 expression was associated with an increased risk of death in stage IV patients-only (n ¼ 56, Figures 5A, 5B and 6A ). The same analysis performed for PPARG showed that low expression levels were associated with a poorer outcome when tumor stage IV patients-only were considered (P ¼ 0.009), in line with published data (Ogino et al., 2009; Pancione et al., 2010b) (Supplementary Figures  5C, 5D and 6B). Finally, a 2-by-2 log-rank test referred to all tumor stages revealed that only the UHRF1 low / PPARG high versus UHRF1 high /PPARG low groups discriminate patients' survival (P ¼ 0.05), especially when referred to stage IV patients-only (P ¼ 0.017) (Figures 7a  and b, Supplementary Figure 6C ). High UHRF1 expression was also correlated with the advanced tumor grade (grade III/IV, Po0.05) (Supplementary Table 1) . Taken together, these results corroborate our in vivo data regarding the association of UHRF1 with tumor grade and the relevant role that the relationship of UHRF1 with PPARG may have in CRC progression.
Discussion
Epigenetic mechanisms contribute to CRC initiation and progression being involved in transcription repression of many TSGs. UHRF1 is emerging as a key coordinator of these events as it regulates both DNA methylation and histone modifications, contributing to tumor progression (Unoki et al., 2004; Bostick et al., 2007; Papait et al., 2007; Sharif et al., 2007) . Its role in CRC has not been addressed yet. We investigated the relationship between UHRF1 and PPARG and provide the first evidence that UHRF1 negatively regulates PPARG and is associated with a higher proliferative and migration potential. Furthemore, we demonstrate that UHRF1 coordinates PPARG epigenetic silencing. In PPARG-negative cells, UHRF1 is, in fact, recruited on the PPARG promoter where it interacts with other regulatory factors required for DNA and histone methylation. In agreement with the data in the literature, DNMT3b is recruited on the PPARG promoter providing support to its involvement in gene repression and colon tumorigenesis (Linhart et al., 2007; Nosho et al., 2009; Ibrahim et al., 2011) . DNMT1 and DNMT3a seem to have a lower impact on PPARG silencing as they are not recruited on the promoter; the differential recruitment of DNMT3a may reflect the very low protein levels detected in the cells analyzed. Histone H3K9 and H3K27 trimethylation are crucial heterochromatin marks and have been associated with (Pancione et al., 2010b; Fullgrabe et al., 2011; Nakazawa et al., 2011; Varier and Timmers, 2011) . We have already shown that H3K27me3 is present on this promoter along with its specific methyltransferase EZH2 (Pancione et al., 2010b) ; here, we provide evidence that H3K9me2 and H3K9me3 are engaged along with Suv39H1 to silence PPARG in CRC cells, in line with recent reports showing that CRC progression correlates with higher levels of Suv39H1 and the presence of these repressive histone marks on promoter sequences (Fullgrabe et al., 2011; Varier and Timmers, 2011) . Consistently, UHRF1 depletion is associated with PPARG re-expression through DNA demethylation at the promoter region and H3K9 and H3K27 demethylation, likely due to displacement of EZH2, MeCP2 and Suv39H1, confirming previous data on their physical interactions with UHRF1 (Unoki et al., 2004; Meilinger and Fellinger, 2009; Alhosin et al., 2011) . Our data support that PPARG epigenetic deregulation is coordinated by UHRF1 through both DNA and histone methylation. Two-and threemethylated H3K9 have been associated with DNA methylation, while H3K27me3 seems to be self-sufficient (d) Relationship between UHRF1 expression assessed by immunohistochemistry and tumor grade (from G1 to G4). For each bar the numbers of the corresponding patients are reported. (e) UHRF1 expression was related to overall patients' survival referred to tumor stages III-IV (n ¼ 45). (f) The combination of UHRF1 and PPARG expression was related to the overall survival analysis referred to all tumor stages (I-IV; n ¼ 110). *Po0.05, **Po0.01.
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L Sabatino et al to repress some TSGs in tumor progression (Kondo et al., 2008; Cheng and Blumenthal, 2010) . In the PPARG case, they converge to fully repress the gene. UHRF1 silencing reactivates also other TSGs, like E-cadherin and RARb, whose expression is downregulated in the CRC cells analyzed. UHRF1, thus, emerges as an important epigenetic regulator of gene expression in CRC. Whether it coordinates the epigenetic silencing of additional TSGs needs to be further investigated. Cells overexpressing UHRF1 present enhanced growth and migration rate and morphological features resembling those occurring in EMT. Likewise, high UHRF1-expressing tumors are characterized by a completely subverted structure and an undifferentiated phenotype, events in which UHRF1 might have a pivotal role. We have shown that PPARG silencing in CRC cells is accompanied by phenotypic changes overlapping those reported here following UHRF1 ectopic expression (Pancione et al., 2010b) ; it is tempting to speculate that the present results might be largely attributed to PPARG silencing. UHRF1 and PPARG may be then part of a regulatory network in which their coordinated and inverse expressions converge towards tumor progression. More experiments are needed to fully elucidate the role of UHRF1 and PPARG in this pathway.
The results obtained in our series in vivo support a role for UHRF1 in colon tumorigenesis. High UHRF1 levels are associated with a more advanced tumor grade (grades 3 and 4), as recently shown in lung, bladder and prostate cancers (Meilinger and Fellinger, 2009; Phe et al., 2010; Alhosin et al., 2011) . High UHRF1 expression is also associated with a shorter survival only in advanced stages (stages III-IV). Interestingly, the prognostic significance of UHRF1 becomes relevant in combination with low PPARG expression even when referred to all tumor stages. Our in vivo data reveal that also the UHRF1 low /PPARG low combination has a poor prognostic value, underscoring the predominant role of low PPARG expression in CRC, as reported (Ogino et al., 2009; Pancione et al., 2010b) . The results suggest that different pathways such as chromosomal instability or post-transcriptional events might regulate PPARG expression in a subgroup of tumors, independently from the epigenetic silencing carried out by UHRF1. The role of UHRF1 and of the UHRF1/PPARG association in CRC development requires further investigations. The results from the independent dataset confirm the significant correlation between UHRF1 overexpression and stage IV tumors, providing strong support to our findings. Also in this set the implication of UHRF1 modifications only in advanced tumors remains to be clarified. Based on our data, we support the notion that UHRF1 overexpression occurs in later stages in colon carcinogenesis. In addition, high UHRF1 expression may contribute to the phenotypic changes of the tumors by inducing the EMT process, a key event in metastasis formation.
In conclusion, we demonstrate that UHRF1 regulates PPARG epigenetic silencing through its recruitment on the PPARG promoter in vitro. UHRF1 overexpression Figure 7 Correlation of UHRF1 and PPARG expression with patients' survival in an independent dataset. The combination of UHRF1 and PPARG expression was related to patients' prognosis, considering all pathological stages (Stages I-IV) (a); or stage IV patients-only (b). The P value is reported in each graph.
UHRF1 and PPARG in colon tumorigenesis L Sabatino et al and PPARG silencing are strictly associated with a more undifferentiated tumor phenotype. The prognostic significance of UHRF1 is related to tumor stage and depends upon PPARG low expression levels. This study provides the first evidence of the important role that the relationship between UHRF1 and PPARG has in colon tumorigenesis. These data might open new promising research avenues towards the use of epidrugs in the modulation of this pathway.
Materials and methods
Cell lines and transfections
The three cell lines derived from human CRCs used in this study (HT29, HCT116 and RKO) were cultured as reported (Pancione et al., 2010b) . HT29 cells were transfected with the UHRF1 full-length cDNA or with an empty expression vector as a control, using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. Among the G418 resistant clones, clones #2 and #6, expressing the higher UHRF1 levels, were characterized; clone #6 was used in the experiments reported. To knock down UHRF1, RKO and HCT116 cells were transiently transfected with a retroviral vector PSM2C carrying either a shRNA targeting UHRF1 mRNA (sh-UHRF1 cat. N.RHS1764-9098093; sh-UHRF1 #2 cat. no. RHS1764-9700150, Open Biosystems Products, Huntsville, AL, USA) or an unrelated shRNA as a control. Short hairpin RNA targeting PPARG mRNA was also used (Pancione et al., 2010b) . To increase the silencing efficiency, two rounds of transfection were performed. Both transiently or stably transfected cells were harvested for DNA, RNA and proteins isolation.
Western Blot, coimmunoprecipitation and immunohistochemical analysis Western blot analysis on protein extracts from CRC cell lines, tumor tissues and adjacent normal mucosa was performed as reported (Pancione et al., 2010a, b) . The following antibodies were used: anti-PPARG (E-8), anti-RARb (C-19), Cyclin D1 (A-12) (Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA); anti-E-cadherin (610405) (BD Transduction Laboratories, Becton Drive Franklin Lakes, NJ, USA); anti-b-actin (A5441) (Sigma-Aldrich, St Louis, MO, USA); anti DNMT1, DNMT3a and 3b (Abcam, Cambridge, MA, USA). A monoclonal antibody anti-hUHRF1 was a gift from Prof. Bonapace. Co-immunoprecipitation assays were carried out as reported (Kim et al., 2009) . Immunohistochemical and haematoxylin and eosin staining analyses were performed as reported (Pancione et al., 2010a, b) . Nuclear UHRF1 immunostaining in tumor tissues was evaluated according to the total number of positive cells in at least five low-power fields ( Â 100) as follows: weak (0-10% positive cells), moderate (410-50%) and intense (450%). The correlation between UHRF1 and Ki67 staining was performed as previously reported (Bruna et al., 2007) .
ChIP and methylated DNA immunoprecipitation assay Quantitative ChIP assay was employed to analyze chomatin modifications and the recruitment of UHRF1 on the PPARG promoter region; the primers and methods used have been reported (Pancione et al., 2010b) . Antibodies raised against: H3K9me2, H3K9me3, H4K16ac, DNMT1, DNMT3b, UHRF1 (Abcam), DNMT3a (Cell Signaling Technology, Inc., Danvers, MA, USA), H3K27me3 (Millipore, Billerica, MA, USA), and purified IgG (Santa Cruz Biotechnology Inc.) were used. Two DNA segments from E-cadherin and GAPDH promoters were used as positive and negative controls, respectively, in semi-quantitative ChIP experiments. The sequences of the primers utilized are the following: E-cadherin For. 5 0 -GAA CTCAGCCAAGTGTAAAAGC-3 0 ; Rev. 5 0 -AG ACGCGGTGACCCTCTA-3 0 ; GAPDH For. 5 0 -TACTAGCG GTTTTACGGGCG-3 0 ; Rev. 5 0 -TCGAACAGGAGGAGC AGAGAGCGA-3 0 ; the amplified products were then analyzed on 2% agarose gels. Methylated DNA immunoprecipitation assay was carried out as recommended by the supplier (Diagenode, Liege, Belgium) (Pancione et al., 2010b) .
RNA extraction and semi-quantitative reverse transcription-PCR Total RNA was isolated with Trizol (Invitrogen). Reverse transcription-PCR (RT-PCR) was made using Superscript II (Invitrogen). Quantitative RT-PCR was performed on 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using SYBR Green PCR Master Mix (Invitrogen) with the specific primers reported in Supplementary Table 2 (Burchill et al., 1995; Shen et al., 2008; Kumar et al., 2010; Pancione et al., 2010b) . The 18S RNA served as an internal control.
Proliferation, apoptosis and migration assays MTT assay (Sigma-Aldrich) was performed as previously reported (Pancione et al., 2010b) . The proliferation rate was also evaluated by a colony forming assay of cells plated at 10 cells per cm 2 , incubated for 7 days and stained with crystal violet. The replicative potential of each colony, expressed as dimension of colonies in triplicate, was analyzed by QuantityOne (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK) and ImageJ 1.44 software (ImageJ, U.S. NIH, Bethesda, MD, USA). Apoptosis was assessed with the Caspase-3 Colorimetric Detection Kit (BioScientific, Austin, TX, USA) following the manufacturers' instructions. The apoptotic rate was also evaluated by Flow cytometric analysis using propidium iodide staining and by TUNEL staining (Promega, Madison, WI, USA), as reported. Cell motility was measured by woundhealing assay at 24 h, as reported (Pancione et al., 2010b) .
DNA bisulphite modification and Methylation-Specific PCR DNA methylation analysis was carried out by methylationspecific PCR assay as reported (Pancione et al., 2010b) . Two PPARG promoter regions were analyzed: M2 (À270/À151) and M3 (À358/À235) from the transcription start site. Universally unmethylated or methylated DNA (Qiagen GmbH, Hilden, Germany) were used as control in each reaction.
Tumor samples A total of 110 patients (62 men and 48 women) with primary sporadic CRC were included in this study. The mean age of patients was 70.5±12.01. Both paraffin embedded and liquid nitrogen frozen specimens were analyzed. Each tumor sample was matched with the adjacent apparently normal mucosa removed during the same surgery. Tumors were classified and graded according to the criteria of the TNM and tumor stages I-IV classification systems, as reported (Pancione et al., 2010a, b) . Stage I were n ¼ 2; stage II n ¼ 63; stage III n ¼ 25 and stage IV n ¼ 20, respectively. None of the patients had a familial history of intestinal dysfunction or CRC, had received chemotherapy or radiation before resection nor had taken non-steroidal anti-inflammatory drugs on a regular basis. Conventional post-operative treatments were provided to all patients, depending upon the severity of the disease. Overall length of survival was calculated starting from the first surgery.
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Patients were followed up for a median of 64±21.5 months or until death. This study was carried out according to the principles of the Declaration of Helsinki and approved by the Institutional Review Board of Fatebenefratelli Hospital in Benevento. All patients provided written informed consent for the collection of samples and subsequent analysis.
Statistics
All statistical analyses were made using SPSS (version 15.0) for Windows (IBM SPSS Corporation, Armonk, NY, USA) and R/Bioconductor. Association between UHRF1 expression and tumor stage was assessed using the w 2 -test or the Spearman's rank test, as indicated. The Kaplan-Meier method was used to estimate survival; the log-rank test was used to test differences between the survival curves. Data were reported as mean ±s.d. and mean values were compared using the Student's t-test or Mann-Whitney test. Results were considered statistically significant when a Pp0.05 was obtained.
Independent dataset analysis
To validate the correlation between UHRF1 and/or PPARG expression and patients' outcome, two independent CRC cDNA microarray datasets, publicly available, annotated in GEO, respectively, as GSE17537 and GSE1753, part of a super series GSE17538 were analyzed. Fifty-five patients come from Vanderbilt Medical Center and 177 from Moffitt Cancer Center (Smith et al., 2010) . Out of these 232 patients, for UHRF1 expression 100 were included in the 1st quartile; 39 in the 2nd and 3rd quartiles; 93 in the 4th quartile. For PPARG, 97 and 94 were included in the 1st and 4th quartile, respectively. Only those included in the 1st and 4th quartiles were taking into account to establish UHRF1 or PPARG down-or overexpressing tumors, respectively. To evaluate how UHRF1 expression influences survival, we divided the samples in two groups according to UHRF1 levels (low or high) and the survival curves were set accordingly. In the log-rank test the dataset was analyzed as a whole or divided in four subsets, one for each stage, and analyzed individually. The size of each subset was different depending on the available data for that particular stage in the dataset. Finally, the Fisher's exact test evaluated the correlation of a specific UHRF1 gene expression pattern with tumor grade.
